View our Industry Expert Theater Presentation
Presented at the 2024 ASCO® Gastrointestinal (GI) Cancers Symposium
Impact of liver function on survival outcomes during treatment with camrelizumab + rivoceranib vs sorafenib in uHCC patients
Presenter: Natalia Raphael, PhD
Executive Director, Medical Affairs
Session Description: Impact of baseline liver reserve and drug-induced hepatotoxicity (DIH) on survival outcomes assessed; time to resolution/discontinuation; impact on quality of life (QoL) of DIH determined. Results of this post-hoc analysis may have implications for selection of initial and subsequent therapies for uHCC patients.
Not an official event of the 2024 ASCO® Gastrointestinal (GI) Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation. Not CME-accredited.
Review our latest data
View the poster presentations
See the phase 3 study results published in The Lancet
At ESMO 2022, we presented our proffered paper on the phase 3 study results comparing rivoceranib in combination with camrelizumab vs sorafenib as a first-line therapy for unresectable hepatocellular carcinoma (uHCC). Look how far we’ve come!
See the phase 3 study results published recently in The Lancet showing a statistically significant and clinically meaningful benefit in progression-free survival and overall survival compared with sorafenib.
Stay connected
Sign up to receive important information about rivoceranib, camrelizumab, company news and updates, or to connect with a member of our team.
